Private GLP-1 prescribing: what follow-up is often missing

The private prescribing gap

Private GLP-1 prescribing in the UK expanded rapidly from 2023 onward. The model that emerged — online consultation, prescription, monthly supply — is efficient for access. It is often inadequate for clinical management. The gap is not in the prescription itself; it is in what happens after: blood pressure monitoring, medication interaction review, diabetes management, blood test interpretation, and structured stopping plans.

This is not a critique of the prescribers involved — many are competent and well-intentioned. It is a structural observation about what an online prescription model can and cannot deliver at scale.

What is commonly missing: blood pressure monitoring

Significant weight loss reduces blood pressure reliably. If a patient is on antihypertensives and loses 15 kg on tirzepatide, their antihypertensives may now be excessive — causing dizziness, fatigue, and falls risk. Private prescribing services rarely have the clinical infrastructure to identify and act on this. It requires blood pressure measurement, medication review, and a GP conversation — none of which are built into a prescription renewal model.

Many patients manage this independently, which means many do not manage it at all. See blood pressure after weight loss for the detail on what needs reviewing and when.

What is commonly missing: diabetes medication review

Patients with type 2 diabetes are often on multiple glucose-lowering agents. GLP-1 medication adds to these. Significant weight loss changes the glucose picture. Sulphonylureas at doses appropriate for a heavier, less well-controlled patient may cause hypoglycaemia in a patient who has lost 20 kg on tirzepatide. This requires active management — dose reduction or cessation of other agents — which private prescribing services are not equipped to provide. [1]

The patient's GP should be managing this, but if the private prescribing has not been communicated to the GP (as is common), the GP does not know to review it.

What is commonly missing: blood test review

Lipids, liver enzymes, kidney function, and HbA1c all change with significant weight loss. Private prescribing models typically include an initial blood test but not systematic follow-up testing at meaningful intervals. Patients using CGMs, Medichecks panels, or other self-directed testing often have data that nobody has interpreted in the context of their medication and weight change. A Clinical Data Review addresses exactly this gap.

What is commonly missing: a stopping plan

The majority of patients who stop private GLP-1 medication do so without a structured exit plan. The prescription simply ends. No monitoring framework, no blood pressure check, no diabetes medication adjustment, no response threshold, no written plan. The consequences — predictable appetite return, weight regain, cardiometabolic reversal — are then managed in isolation, often with significant distress and confusion about what went wrong.

This is the gap that a GLP-1 Exit Strategy Review is specifically designed to address.

What good follow-up looks like

Good clinical follow-up during GLP-1 treatment includes: blood pressure check at 4, 12, and 24 weeks and whenever dose changes; blood tests at baseline, 3 months, and 12 months (at minimum); medication list review at each dose change; diabetes medication adjustment as HbA1c and weight change; and a structured stopping plan before the last dose. This is not exotic — it is basic clinical management of a pharmacologically active treatment with systemic effects. The gap in private prescribing is the absence of this structure, not the prescribing itself.